Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 6:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: E.Coli Infections Clear all
Completed No phase listed Observational

Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy

NCT00915213
View directory record Official record
Conditions
Bacterial Infection
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Irvine, California • Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Sublingual dmLT for ETEC

NCT02052934
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 24, 2026, 6:38 AM EDT
Completed No phase listed Observational

Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli

NCT00573235
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

NCT01382095
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Sep 24, 2026, 6:38 AM EDT
Completed No phase listed Observational

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

NCT04117113
View directory record Official record
Conditions
E. Coli Infection
Interventions
Not listed
Lead sponsor
UMC Utrecht
Other
Eligibility
60 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 24, 2026, 6:38 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

NCT03038243
View directory record Official record
Conditions
Shigella Sonnei Dysenteries
Interventions
Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT), Shigella flexneri 2a whole cell (Sf2aWC) vaccine, Placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

NCT01644565
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

NCT04634513
View directory record Official record
Conditions
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Interventions
strain CVD 1208S-122, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 24, 2026, 6:38 AM EDT
Recruiting Phase 1 Interventional

Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria

NCT06559618
View directory record Official record
Conditions
Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
Interventions
Phage Therapy, Placebo
Drug · Other
Lead sponsor
Barbara Trautner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 24, 2026, 6:38 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 24, 2026, 6:38 AM EDT
Completed No phase listed Observational

Community - Associated Extended-spectrum Beta-lactamases (ESBL)

NCT00363220
View directory record Official record
Conditions
Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 2 Interventional Results available

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

NCT01595529
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 10 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women

NCT01219595
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Sweetened, dried cranberries, Strawberry Fruit Pieces, Observation
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ACE527 Safety and Immunogenicity Study

NCT00901654
View directory record Official record
Conditions
Enterotoxigenic E. Coli (ETEC) Infection
Interventions
ACE527 vaccine, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Sep 24, 2026, 6:38 AM EDT
Terminated Phase 3 Interventional

Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

NCT00004465
View directory record Official record
Conditions
Hemolytic Uremic Syndrome
Interventions
SYNSORB Pk, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
26
States / cities
Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 24, 2026, 6:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867
View directory record Official record
Conditions
E Coli Infections, Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
Biological · Other
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 24, 2026, 6:38 AM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

NCT04574596
View directory record Official record
Conditions
E Coli Infection
Interventions
no Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
300 participants
Timeline
2020 – 2021
U.S. locations
13
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

NCT03576183
View directory record Official record
Conditions
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Interventions
VLA1701, Placebo, Challenge Strain
Biological · Other
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 24, 2026, 6:38 AM EDT
Withdrawn No phase listed Observational

Ampicillin-sulbactam Resistant E.Coli at UPMC

NCT00619580
View directory record Official record
Conditions
Positive E Coli Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 24, 2026, 6:38 AM EDT
Completed No phase listed Observational

Perinatal Transmission of MDR Bacteria

NCT06148480
View directory record Official record
Conditions
E. Coli Infection, Multi-antibiotic Resistance
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 24, 2026, 6:38 AM EDT
Recruiting Not applicable Interventional

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

NCT06080698
View directory record Official record
Conditions
Gram-negative Bacteremia
Interventions
Intravenous Antibiotics, Oral Antibiotics
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Results available

Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study

NCT00554996
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
E. coli 83972 coated urinary catheter
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 24, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)

NCT03404674
View directory record Official record
Conditions
Diarrhea
Interventions
CssBA, dmLT
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 24, 2026, 6:38 AM EDT